Patents by Inventor Robert M. Kessler
Robert M. Kessler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200197388Abstract: The present invention relates to improved compositions and methods for the treatment or prevention of various diseases, including forms of depression, including, for example, breakthrough depression and treatment-refractory depression, and other mood disorders, as well as Parkinson's disease, bipolar disorder, bipolar disorder, attention deficit disorder (ADHD), Restless Leg Syndrome (RLS), and obesity. In some embodiments, the compositions and methods comprise low dose naltrexone or related opioid antagonists.Type: ApplicationFiled: March 5, 2020Publication date: June 25, 2020Inventors: David M. BEAR, Robert M. KESSLER
-
Publication number: 20200188389Abstract: Methods and compositions are provided for preventing or reversing loss of the therapeutic effect of a drug, where the loss is associated with the repeated administration of the drug to a patient. The method includes administering to the patient a dopamine receptor agonist or partial agonist or a drug that increases the extracellular level of dopamine by enhancing release of dopamine, decreasing the removal of dopamine from the extracellular space, enhancing the synthesis of dopamine within the brain, or decreasing metabolic degradation of dopamine; and also administering to the patient an opioid receptor antagonist in an ultra-low dose amount, wherein the ultra-low dose amount is effective to prevent or reverse loss of therapeutic effects associated with the repeated administration of the drug to the patient. The methods are useful for various treatments, including treating Parkinson's Disease, Restless Leg Syndrome, depression, schizophrenia, psychostimulant drug abuse, or attention deficit disorder.Type: ApplicationFiled: February 24, 2020Publication date: June 18, 2020Inventors: David M. BEAR, Robert M. KESSLER
-
Publication number: 20190343829Abstract: The present invention relates to improved compositions and methods for the treatment or prevention of various diseases, including forms of depression, including, for example, breakthrough depression and treatment-refractory depression, and other mood disorders, as well as Parkinson's disease, bipolar disorder, bipolar disorder, attention deficit disorder (ADHD), Restless Leg Syndrome (RLS), and obesity. In some embodiments, the compositions and methods comprise low dose naltrexone or related opioid antagonists.Type: ApplicationFiled: July 23, 2019Publication date: November 14, 2019Inventors: David M. BEAR, Robert M. KESSLER
-
Publication number: 20190328726Abstract: Methods and compositions are provided for preventing or reversing loss of the therapeutic effect of a drug, where the loss is associated with the repeated administration of the drug to a patient. The method includes administering to the patient a dopamine receptor agonist or partial agonist or a drug that increases the extracellular level of dopamine by enhancing release of dopamine, decreasing the removal of dopamine from the extracellular space, enhancing the synthesis of dopamine within the brain, or decreasing metabolic degradation of dopamine; and also administering to the patient an opioid receptor antagonist in an ultra-low dose amount, wherein the ultra-low dose amount is effective to prevent or reverse loss of therapeutic effects associated with the repeated administration of the drug to the patient. The methods are useful for various treatments, including treating Parkinson's Disease, Restless Leg Syndrome, depression, schizophrenia, psychostimulant drug abuse, or attention deficit disorder.Type: ApplicationFiled: July 10, 2019Publication date: October 31, 2019Inventors: David M. Bear, Robert M. Kessler
-
Publication number: 20190231772Abstract: The present invention relates to improved compositions and methods for the treatment or prevention of various diseases, including forms of depression, including, for example, breakthrough depression and treatment-refractory depression, and other mood disorders, as well as Parkinson's disease, bipolar disorder, bipolar disorder, attention deficit disorder (ADHD), Restless Leg Syndrome (RLS), and obesity. In some embodiments, the compositions and methods comprise low dose naltrexone or related opioid antagonists.Type: ApplicationFiled: April 9, 2019Publication date: August 1, 2019Inventors: David M. BEAR, Robert M. KESSLER
-
Publication number: 20190083488Abstract: Methods and compositions are provided for preventing or reversing loss of the therapeutic effect of a drug, where the loss is associated with the repeated administration of the drug to a patient. The method includes administering to the patient a dopamine receptor agonist or partial agonist or a drug that increases the extracellular level of dopamine by enhancing release of dopamine, decreasing the removal of dopamine from the extracellular space, enhancing the synthesis of dopamine within the brain, or decreasing metabolic degradation of dopamine; and also administering to the patient an opioid receptor antagonist in an ultra-low dose amount, wherein the ultra-low dose amount is effective to prevent or reverse loss of therapeutic effects associated with the repeated administration of the drug to the patient. The methods are useful for various treatments, including treating Parkinson's Disease, Restless Leg Syndrome, depression, schizophrenia, psychostimulant drug abuse, or attention deficit disorder.Type: ApplicationFiled: November 15, 2018Publication date: March 21, 2019Inventors: David M. BEAR, Robert M. KESSLER
-
Publication number: 20180318289Abstract: The present invention relates to improved compositions and methods for the treatment or prevention of various diseases, including forms of depression, including, for example, breakthrough depression and treatment-refractory depression, and other mood disorders, as well as Parkinson's disease, bipolar disorder, bipolar disorder, attention deficit disorder (ADHD), Restless Leg Syndrome (RLS), and obesity. In some embodiments, the compositions and methods comprise low dose naltrexone or related opioid antagonists.Type: ApplicationFiled: July 10, 2018Publication date: November 8, 2018Inventors: David M. BEAR, Robert M. KESSLER
-
Publication number: 20170189393Abstract: Methods and compositions are provided for preventing or reversing loss of the therapeutic effect of a drug, where the loss is associated with the repeated administration of the drug to a patient. The method includes administering to the patient a dopamine receptor agonist or partial agonist or a drug that increases the extracellular level of dopamine by enhancing release of dopamine, decreasing the removal of dopamine from the extracellular space, enhancing the synthesis of dopamine within the brain, or decreasing metabolic degradation of dopamine; and also administering to the patient an opioid receptor antagonist in an ultra-low dose amount, wherein the ultra-low dose amount is effective to prevent or reverse loss of therapeutic effects associated with the repeated administration of the drug to the patient. The methods are useful for various treatments, including treating Parkinson's Disease, Restless Leg Syndrome, depression, schizophrenia, psychostimulant drug abuse, or attention deficit disorder.Type: ApplicationFiled: March 22, 2017Publication date: July 6, 2017Inventors: David M. Bear, Robert M. Kessler
-
Publication number: 20160310484Abstract: The present invention relates to improved compositions and methods for the treatment or prevention of various diseases, including forms of depression, including, for example, breakthrough depression and treatment-refractory depression, and other mood disorders, as well as Parkinson's disease, bipolar disorder, bipolar disorder, attention deficit disorder (ADHD), Restless Leg Syndrome (RLS), and obesity. In some embodiments, the compositions and methods comprise low dose naltrexone or related opioid antagonists.Type: ApplicationFiled: January 28, 2016Publication date: October 27, 2016Inventors: David M. Bear, Robert M. Kessler
-
Patent number: 9278094Abstract: The present invention relates to improved compositions and methods for the treatment or prevention of various diseases, including forms of depression, including, for example, breakthrough depression and treatment-refractory depression, and other mood disorders, as well as Parkinson's disease, bipolar disorder, bipolar disorder, attention deficit disorder (ADHD), Restless Leg Syndrome (RLS), and obesity. In some embodiments, the compositions and methods comprise low dose naltrexone or related opioid antagonists.Type: GrantFiled: March 5, 2015Date of Patent: March 8, 2016Assignee: PHARMORX THERAPEUTICS, INC.Inventors: David M. Bear, Robert M. Kessler
-
Publication number: 20150342946Abstract: The present invention relates to improved compositions and methods for the treatment or prevention of various diseases, including forms of depression, including, for example, breakthrough depression and treatment-refractory depression, and other mood disorders, as well Parkinson's disease, bipolar disorder, bipolar disorder, attention deficit disorder (ADHD), Restless Leg Syndrome (RLS), and obesity. In some embodiments, the compositions and methods comprise low dose naltrexone or related opioid antagonists.Type: ApplicationFiled: January 30, 2014Publication date: December 3, 2015Applicant: PharmoRX Therapeutics, Inc.Inventors: David M Bear, Robert M. Kessler
-
Publication number: 20150202199Abstract: The present invention relates to improved compositions and methods for the treatment or prevention of various diseases, including forms of depression, including, for example, breakthrough depression and treatment-refractory depression, and other mood disorders, as well as Parkinson's disease, bipolar disorder, bipolar disorder, attention deficit disorder (ADHD), Restless Leg Syndrome (RLS), and obesity. In some embodiments, the compositions and methods comprise low dose naltrexone or related opioid antagonists.Type: ApplicationFiled: March 5, 2015Publication date: July 23, 2015Inventors: David M. Bear, Robert M. Kessler
-
Publication number: 20150080422Abstract: Methods and compositions are provided for preventing or reversing loss of the therapeutic effect of a drug, where the loss is associated with the repeated administration of the drug to a patient. The method includes administering to the patient a dopamine receptor agonist or partial agonist or a drug that increases the extracellular level of dopamine by enhancing release of dopamine, decreasing the removal of dopamine from the extracellular space, enhancing the synthesis of dopamine within the brain, or decreasing metabolic degradation of dopamine; and also administering to the patient an opioid receptor antagonist in an ultra-low dose amount, wherein the ultra-low dose amount is effective to prevent or reverse loss of therapeutic effects associated with the repeated administration of the drug to the patient. The methods are useful for various treatments, including treating Parkinson's Disease, Restless Leg Syndrome, depression, schizophrenia, psychostimulant drug abuse, or attention deficit disorder.Type: ApplicationFiled: September 25, 2014Publication date: March 19, 2015Applicant: PharmoRx Therapeutics, Inc.Inventors: David M. Bear, Robert M. Kessler
-
Patent number: 8883831Abstract: Methods and compositions are provided for preventing or reversing loss of the therapeutic effect of a drug, where the loss is associated with the repeated administration of the drug to a patient. The method includes administering to the patient a dopamine receptor agonist or partial agonist or a drug that increases the extracellular level of dopamine by enhancing release of dopamine, decreasing the removal of dopamine from the extracellular space, enhancing the synthesis of dopamine within the brain, or decreasing metabolic degradation of dopamine; and also administering to the patient an opioid receptor antagonist in an ultra-low dose amount, wherein the ultra-low dose amount is effective to prevent or reverse loss of therapeutic effects associated with the repeated administration of the drug to the patient. The methods are useful for various treatments, including treating Parkinson's Disease, Restless Leg Syndrome, depression, schizophrenia, psychostimulant drug abuse, or attention deficit disorder.Type: GrantFiled: February 4, 2013Date of Patent: November 11, 2014Assignee: PharmoRx Therapeutics, Inc.Inventors: David M. Bear, Robert M. Kessler
-
Publication number: 20130190343Abstract: Methods and compositions are provided for preventing or reversing loss of the therapeutic effect of a drug, where the loss is associated with the repeated administration of the drug to a patient. The method includes administering to the patient a dopamine receptor agonist or partial agonist or a drug that increases the extracellular level of dopamine by enhancing release of dopamine, decreasing the removal of dopamine from the extracellular space, enhancing the synthesis of dopamine within the brain, or decreasing metabolic degradation of dopamine; and also administering to the patient an opioid receptor antagonist in an ultra-low dose amount, wherein the ultra-low dose amount is effective to prevent or reverse loss of therapeutic effects associated with the repeated administration of the drug to the patient. The methods are useful for various treatments, including treating Parkinson's Disease, Restless Leg Syndrome, depression, schizophrenia, psychostimulant drug abuse, or attention deficit disorder.Type: ApplicationFiled: February 4, 2013Publication date: July 25, 2013Inventors: David M. Bear, Robert M. Kessler
-
Publication number: 20100168119Abstract: Methods and compositions are provided for preventing or reversing loss of the therapeutic effect of a drug, where the loss is associated with the repeated administration of the drug to a patient. The method includes administering to the patient a dopamine receptor agonist or partial agonist or a drug that increases the extracellular level of dopamine by enhancing release of dopamine, decreasing the removal of dopamine from the extracellular space, enhancing the synthesis of dopamine within the brain, or decreasing metabolic degradation of dopamine; and also administering to the patient an opioid receptor antagonist in an ultra-low dose amount, wherein the ultra-low dose amount is effective to prevent or reverse loss of therapeutic effects associated with the repeated administration of the drug to the patient. The methods are useful for various treatments, including treating Parkinson's Disease, Restless Leg Syndrome, depression, schizophrenia, psychostimulant drug abuse, or attention deficit disorder.Type: ApplicationFiled: October 21, 2009Publication date: July 1, 2010Applicant: PHARMORx, Inc.Inventors: David M. Bear, Robert M. Kessler
-
Patent number: 5480631Abstract: Novel, substituted benzamides in radioiodinated form are useful in radiopharmaceutical compositions in nuclear medicine as imaging agents to detect, visualize, and analyze the distribution and function of the dopamine D2 receptor in the mammalian brain. These compounds have a specific combination of lipophilicity and dopamine D2 receptor affinity required to attain a required image contrast. The iodinated benzamides identified by the above discovery can be made by reacting a trialkyltin substituted benzamide with an acid in the presence of radioactive iodine which, in turn, is generated by in situ oxidation of an appropriate iodide nuclide salt.Type: GrantFiled: May 28, 1992Date of Patent: January 2, 1996Assignee: Vanderbilt UniversityInventors: Tomas De Paulis, Robert M. Kessler, Howard E. Smith, Aaron Janowski, Jeffrey A. Clanton
-
Patent number: 5154913Abstract: Novel, substituted benzamides in radioiodinated form are useful in radiopharmaceutical compositions in nuclear medicine as imaging agents to detect, visualize, and analyze the distribution and function of the dopamine D-2 receptor in the mammalian brain. The substituted benzamides and their racemic mixtures or their optically resolved enantiomers can be made by reacting a trialyltin substituted benzamide with an acid in the presence of radioactive iodine, generated by in situ oxidation of an appropriate iodide nuclide salt.Type: GrantFiled: May 28, 1991Date of Patent: October 13, 1992Assignee: Vanderbilt UniversityInventors: Tomas de Paulis, Robert M. Kessler, Howard E. Smith, Aaron Janowsky, Jeffrey A. Clanton
-
Patent number: 4766381Abstract: A method of inversion spin echo magnetic resonance imaging includes providing a specimen positioned within a main magnetic field, a source of RF signals, a receiver for receiving signals emitted from the specimen responsive to the RF pulses and emitting responsive output signals, a computer for receiving the output signals from the receiver and establishing image information related thereto and a visual display for displaying images obtained from the image information. During an initial echo period, imposing three pulses on the main magnetic field with the first and third pulses having a first value and the second pulse having a second value which may be approximately double the first value, creating an echo with the second pulse and the third pulse converting this echo into negative longitudinal magnetization.Type: GrantFiled: August 12, 1987Date of Patent: August 23, 1988Assignee: Vanderbilt UniversityInventors: Thomas E. Conturo, Robert M. Kessler